Palbociclib (PD-0332991) HCl

Name: Palbociclib (PD-0332991) HCl
Brand: Selleck Chemicals
SKU: S1116
Rating: 5 (193 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1116

193 publications

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 193 publications

Nature, 2020, 17

PubMed: 32555459 ( click the link to review the publication )

Cell, 2020, 16;181(2):424-441.e21.

PubMed: 32234521 ( click the link to review the publication )

Cell Stem Cell, 2020, 27(1):50-63.e5

PubMed: 32619518 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Cell, 2018, 9;34(1):56-68.e9

PubMed: 29990501 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Nat Commun, 2020, 2;11(1):2760

PubMed: 32488085 ( click the link to review the publication )

Nat Commun, 2020, 11(1):385

PubMed: 31959756 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-0943-5

PubMed: 32591645 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2706

PubMed: 32086342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6)

PubMed: 32236513 ( click the link to review the publication )

J Cell Biol, 2020, 2;219(3)

PubMed: 32211891 ( click the link to review the publication )
Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Cancers (Basel), 2020, 6;12(4)

PubMed: 32268485 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32197329 ( click the link to review the publication )

Cells, 2020, 26;9(4)

PubMed: 32225025 ( click the link to review the publication )

Cancer Discov, 2020, 13;CD-19-1390

PubMed: 32404308 ( click the link to review the publication )

Cancer Discov, 2020, 4;CD-20-0329

PubMed: 32499221 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:280

PubMed: 32624705 ( click the link to review the publication )

Breast Cancer, 2020, 10.1007/s12282-020-01090-3

PubMed: 32297248 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Clin Transl Med, 2020, 10(1):182-198

PubMed: 32508030 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e11031

PubMed: 31512803 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )
Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

Sci Signal, 2019, 12(601):eaay0482

PubMed: 31575731 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )
Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )
Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )
Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

J Mol Cell Biol, 2017, 1;9(2):154-165

PubMed: 27927748 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0181601

PubMed: 28806746 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )
Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

PLoS Pathog, 2016, 12(8):e1005829

PubMed: 27541004 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2016, 310(7):C520-41

PubMed: 26718628 ( click the link to review the publication )

Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Anticancer Res, 2015, 35(12):6623-32

PubMed: 26637878 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )
Blood, 2014, 3;124(1):13-23

PubMed: 24764564 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

J Immunol, 2014, 193(4):1988-97

PubMed: 25015816 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

PLoS Genet, 2013, 9(5):e1003546

PubMed: 23737759 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2722-34

PubMed: 24107447 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )
Clin Cancer Res, 2011, 1;17(13):4513-22

PubMed: 21593195 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	MWPLbY5ie2ViQYPzZZk>		NVry[IdTOjRiaB?=		M36zVmlvcGmkaYTpc44hd2ZiQ1TLOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFIh\|ryP	NVPlR\|VkOjR4NEGxNFM>
COLO205	NX:4VolzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3TXblczKGh?		NGL1UXdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>?	M{\XWlI1PjRzMUCz
U937	MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVS3NkBp		NUTFTWFHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>?	MYGyOFY1OTFyMx?=
MOLM13	M1XR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVr2[lRFPzJiaB?=		M2fkNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR\|IFnUSEBufXSjboSgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0>	NXfkcpBFOjR4NEGxNFM>
MOLM13	M1rLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXq3NkBp		NEjYc5VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh\|ryP	NX2xPW1nOjR4NEGxNFM>
MDA-MB-435	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWKyOEBp		M2LncGlEPTB;MD6xOkDPxE1?	MWSxOVgxOTh\|MR?=
K562	NEH6OWFEgXSxdH;4bYMhSXO\|YYm=		MVi5OkBp	M2\rZmROW09?	NHm3V3BKSzVyPUKg{txO	NF3MSHQzPDRzN{W2Oi=>
DU145	MlHUR5l1d3SxeHnjJGF{e2G7		MXe5OkBp	NIrh[49FVVOR	MlXLTWM2OD15LkWg{txO	MlfFNlQ1OTd3Nk[=
MDA-MB-231	NUDVSmRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPTWWoyKM7:TR?=	MoXNNlQhcA>?	M{jVcGROW09?	NFvEOI5E\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>	NWPOdog4OjR2MUe1OlY>
MCF7	NUjPTpRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvSbmoyKM7:TR?=	Mn\ONlQhcA>?	NXLlS5FiTE2VTx?=	NGTCPG9E\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>	M{DBXlI1PDF5NU[2
MCF7	NVn5RVlHU2mwYYPlJGF{e2G7	MkW3OUDPxE1?	MYWyOEBp	NIXBTolFVVOR	M2nXZWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=	MoT0NlQ1OTd3Nk[=
MDA-MB-231	M{LzfWtqdmG\|ZTDBd5NigQ>?	MVi1JO69VQ>?	M2rSUFI1KGh?	MnvISG1UVw>?	MnvuTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=	MVSyOFQyPzV4Nh?=
MDA-MB-231	MkD6SpVv[3Srb36gRZN{[Xl?	M2n5WVEuOTBizszN	M4XkXFI1KGh?	Ml\6SG1UVw>?	M1j6c4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZR?=	NWnyUJV3OjR2MUe1OlY>
MCF7	NGrKUpNHfW6ldHnvckBCe3OjeR?=	NXHTRpZNOS1zMDFOwG0>	MUeyOEBp	NVLGeJJOTE2VTx?=	MnnF[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen	MWSyOFQyPzV4Nh?=
MDA-MB-231	MmPXSpVv[3Srb36gRZN{[Xl?	MUSwMlUuOSEQvF2=	MUO0PEBp	MW\EUXNQ	NILG[Y9p[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>?	NWHHOXY5OjR2MUe1OlY>
MCF7	NYTE[WhJTnWwY4Tpc44hSXO\|YYm=	NH;KOIYxNjVvMTFOwG0>	MXu0PEBp	NXvVW45YTE2VTx?=	MVHoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>	NWDGfYRiOjR2MUe1OlY>
697	NEnWcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLsUYVmUUN3ME2xOFgvOzhibl2=	MUXTRW5ITVJ?
P12-ICHIKAWA	M{nmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGL6e2lKSzVyPUm2MlA1KG6P	NWHrcoZJW0GQR1XS
NB69	NXHJVJlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTF4MT64JI5O	Ml[zV2FPT0WU
EoL-1	NELYbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTF6Nz6yOkBvVQ>?	MmLLV2FPT0WU
BHT-101	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDMTWM2OD1zOUiuNlUhdk1?	NXPSS\|lRW0GQR1XS
SK-NEP-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3KXWRKSzVyPUKyNE4xOiCwTR?=	NG[xUWJUSU6JRWK=
MHH-NB-11	NWG2dIljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDaTWM2OD1{MkCuNVkhdk1?	NVH6[3NmW0GQR1XS
AsPC-1	NWTkcoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLUTWM2OD1{NUKuOVMhdk1?	M1mzfHNCVkeHUh?=
ES1	MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlH3TWM2OD1{NU[uNlUhdk1?	NFKwXZVUSU6JRWK=
LAMA-84	M3zITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fOUWlEPTB;MkW4MlE6KG6P	M2iwNHNCVkeHUh?=
MOLT-16	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEf1bodKSzVyPUK1PE41QSCwTR?=	NFLOcXFUSU6JRWK=
ES7	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHpcGkyUUN3ME2yO\|MvODlibl2=	NIHHR3FUSU6JRWK=
KY821	NEW4SlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTHTnZ4UUN3ME2zNVQvOSCwTR?=	NYjwcVA3W0GQR1XS
RT-112	MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrmZYM2UUN3ME2zNlEvODVibl2=	NXHQUFJmW0GQR1XS
HL-60	NHHPeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLaUFYzUUN3ME2zOFAvPjZibl2=	M2\aNXNCVkeHUh?=
MOLT-4	M4XLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPqcGNKSzVyPUO0OU4yOyCwTR?=	M3vzW3NCVkeHUh?=
KARPAS-45	NEPyWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPoTWM2OD1\|N{[uNVYhdk1?	MYTTRW5ITVJ?
SK-N-AS	NUOyUZhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mln3TWM2OD1\|OEeuPFMhdk1?	NHS1eFFUSU6JRWK=
CTB-1	MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTRyNT6wNkBvVQ>?	M4XheXNCVkeHUh?=
NKM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHwTWM2OD12MUGuPFkhdk1?	NIjhSGdUSU6JRWK=
HTC-C3	M1ewVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnWR2xKSzVyPUSzNk46PSCwTR?=	NF\DbXpUSU6JRWK=
BE-13	NYX1bnJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zIXmlEPTB;NES0MlI4KG6P	MkK3V2FPT0WU
KOSC-2	Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LKfWlEPTB;NE[2Mlkhdk1?	MWLTRW5ITVJ?
NB14	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTR6Mz61PEBvVQ>?	NIn6b4pUSU6JRWK=
CAL-27	M1vqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1S0PWlEPTB;NEm0MlU6KG6P	Mn\qV2FPT0WU
H9	MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXoemV6UUN3ME20PVUvPDNibl2=	MUDTRW5ITVJ?
RS4-11	M4rlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTVyND63N{BvVQ>?	MWnTRW5ITVJ?
PA-1	NXzBToJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DIS2lEPTB;NUC5Mlg3KG6P	MVzTRW5ITVJ?
MV-4-11	M122d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHiTWM2OD13MUOuPFUhdk1?	NVLwbGc1W0GQR1XS
OS-RC-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTVTWM2OD13MkGuOlIhdk1?	M1TrTHNCVkeHUh?=
RPMI-8226	NHP3fVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37F[mlEPTB;NUK2Mlg3KG6P	Mlf6V2FPT0WU
HGC-27	NIXwTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PIemlEPTB;NU[0Mlk6KG6P	NWDOWmZ5W0GQR1XS
CHP-212	MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7oTWM2OD13OUOuOVkhdk1?	MUDTRW5ITVJ?
NB10	NUfkd25NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEGyRY1KSzVyPUW5PU4yQCCwTR?=	NYSxZmVMW0GQR1XS
HH	M4naemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fpOWlEPTB;NUm5MlQ{KG6P	MXrTRW5ITVJ?
EW-16	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIGyTWZKSzVyPU[wN{42OiCwTR?=	MWfTRW5ITVJ?
ES8	NEPJWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTZyNT6yNUBvVQ>?	NF;GenFUSU6JRWK=
HAL-01	M33lbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnDXFNKSzVyPU[wOU43PyCwTR?=	MVXTRW5ITVJ?
A204	M{[xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjDcIJKSzVyPU[zN{46OSCwTR?=	NWn5Tm5[W0GQR1XS
MHH-PREB-1	M3iwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\JV2JPUUN3ME22N\|YvQTlibl2=	Mn\xV2FPT0WU
EM-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPMTWM2OD14NUCuOlQhdk1?	NI\scFFUSU6JRWK=
BV-173	M13sNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXe2fIVRUUN3ME22OVIvPDhibl2=	MVzTRW5ITVJ?
ONS-76	M{njOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7mOIVlUUN3ME22O\|cvQDJibl2=	MmrnV2FPT0WU
KM-H2	NVflNGI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXXTWM2OD14OUWuOVQhdk1?	MW\TRW5ITVJ?
D-263MG	M1PkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUO1WmdOUUN3ME23NVcvOTJibl2=	MkH6V2FPT0WU
ES3	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfwTHpyUUN3ME23NlgvQTNibl2=	NUWxO4xPW0GQR1XS
VA-ES-BJ	NIW2XIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfpTWM2OD15M{KuNlchdk1?	M1[wd3NCVkeHUh?=
NBsusSR	MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPPTWM2OD15NEKuPVkhdk1?	MWrTRW5ITVJ?
NCI-H520	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7GTWM2OD15NE[uOVIhdk1?	NEe4WXJUSU6JRWK=
ES5	NEXMW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTaTWM2OD15NUKuPEBvVQ>?	MVXTRW5ITVJ?
T-24	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTd5OD63NUBvVQ>?	NXPoPZJlW0GQR1XS
SW962	NEi5T4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoL6TWM2OD16MEiuOlMhdk1?	M361NHNCVkeHUh?=
EW-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRThyOD63OkBvVQ>?	MXrTRW5ITVJ?
RXF393	NVjZUWxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoO3TWM2OD16MUKuO\|khdk1?	M1\mbXNCVkeHUh?=
U251	NWTCe3dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRThzMz64PEBvVQ>?	NF64OXhUSU6JRWK=
CAMA-1	M2SxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTkTWM2OD16M{OuPVQhdk1?	MWHTRW5ITVJ?
JVM-3	NETlUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTh3MT63PEBvVQ>?	NIHGSG5USU6JRWK=
COLO-800	M3S4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M16wWWlEPTB;OEm3Mlc5KG6P	MX7TRW5ITVJ?
OVCAR-5	NF75WXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXy[m5KSzVyPUmwNE4yKG6P	NXjlbpFOW0GQR1XS
LB1047-RCC	MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jVcGlEPTB;OUK3MlU3KG6P	MV7TRW5ITVJ?
SW954	NEeyOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{i0V2lEPTB;OUK5MlQyKG6P	NW\zOYpIW0GQR1XS
J-RT3-T3-5	M3vQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLBdm9KSzVyPUmzOk4xPiCwTR?=	MX;TRW5ITVJ?
Mewo	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTl\|Nj62JI5O	NYewXYY5W0GQR1XS
NCI-H1770	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rE[mlEPTB;OUSwMlU2KG6P	MkC2V2FPT0WU
HO-1-N-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTl4Mj64NUBvVQ>?	MmSyV2FPT0WU
HSC-3	Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHCd3NiUUN3ME25OlYvPDhibl2=	MmmzV2FPT0WU
TYK-nu	NH\RWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIT3W4FKSzVyPUm5PE4zPSCwTR?=	M4r6e3NCVkeHUh?=
KYSE-150	NInG[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4njdGlEPTB;MT6wNFA4PiEQvF2=	M{SzUXNCVkeHUh?=
SN12C	NHX1O25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\iVnhKSzVyPUGuNFA5PzVizszN	MoSwV2FPT0WU
MOLT-13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33WTmlEPTB;MT6wNVQzOSEQvF2=	NGSydZhUSU6JRWK=
TE-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorhTWM2OD1zLkC0PFEzKM7:TR?=	NF7zR4VUSU6JRWK=
DB	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXtW\|V6UUN3ME2xMlA4Ojd\|IN88US=>	NG[2TIlUSU6JRWK=
CAL-39	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlezTWM2OD1zLkC3OVIzKM7:TR?=	MXzTRW5ITVJ?
A3-KAW	NYX6[4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTFwMEi0NFgh\|ryP	NY\RfppIW0GQR1XS
CHP-134	NVzKOo5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHCOVVKSzVyPUGuNVE5ODdizszN	NVrnToxTW0GQR1XS
TGW	NH\ufnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HmdGlEPTB;MT6xNlM6PSEQvF2=	M1XXOXNCVkeHUh?=
QIMR-WIL	M2DmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXKc25KSzVyPUGuNVMyOzRizszN	Mmj2V2FPT0WU
NCI-SNU-1	NFnFPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHObI1KSzVyPUGuNVY{PTRizszN	M1TifHNCVkeHUh?=
CGTH-W-1	M1zjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;Wc5ZKSzVyPUGuNVcyQDZizszN	NVjjdmwyW0GQR1XS
MHH-ES-1	MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTFwMUe5PFYh\|ryP	NF35[4hUSU6JRWK=
LB2241-RCC	M2HVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFwMUi2NkDPxE1?	NHv3O5JUSU6JRWK=
ML-2	NHXCPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\qR49KSzVyPUGuNlA4OzRizszN	MVvTRW5ITVJ?
COR-L23	M{OyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTFwMkK5N\|Mh\|ryP	MUDTRW5ITVJ?
BFTC-905	MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TUTGlEPTB;MT6yOFI3PyEQvF2=	NX;5c3Q3W0GQR1XS
Hs-578-T	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTFwMkW4NVch\|ryP	M4PKXXNCVkeHUh?=
KG-1	Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIe4NmpKSzVyPUGuNlY3QDZizszN	NVLTd4pTW0GQR1XS
HEL	NYS3eXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\SWG5KSzVyPUGuNlk{OzhizszN	NGfjdI5USU6JRWK=
A549	M{T1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEH1WIJKSzVyPUGuNlk{QTlizszN	M4jUNHNCVkeHUh?=
COLO-741	NIK5ZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFwM{KwPFkh\|ryP	M2jiRXNCVkeHUh?=
PC-3	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXJTWM2OD1zLkO1NlIyKM7:TR?=	NITYdWFUSU6JRWK=
HOS	NXnxcZNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELjd3pKSzVyPUGuN\|UzQTZizszN	NYjScHR1W0GQR1XS
HT-1080	NF7DRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7TTWM2OD1zLkO3OVE6KM7:TR?=	NUfhcFJIW0GQR1XS
TE-8	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHhTWM2OD1zLkSxO\|c1KM7:TR?=	NUXsVY5FW0GQR1XS
BHY	M2D5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvKTWM2OD1zLkS2PVI{KM7:TR?=	NWf5eGx[W0GQR1XS
BB65-RCC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlT3TWM2OD1zLkWwOVI5KM7:TR?=	NVzFcpZiW0GQR1XS
HN	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzFNGtKSzVyPUGuOVQxPzFizszN	MmmzV2FPT0WU
NCI-H441	NF\iW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nZV2lEPTB;MT61OFkxPyEQvF2=	MlG2V2FPT0WU
RPMI-8866	MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrJTWM2OD1zLkW4OVA4KM7:TR?=	M4\od3NCVkeHUh?=
CAL-62	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jBXWlEPTB;MT62NFg3OiEQvF2=	MWrTRW5ITVJ?
MG-63	M3KzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETkUnhKSzVyPUGuOlE5OTNizszN	M{HzdnNCVkeHUh?=
SK-LU-1	NEDOOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHq0b5RKSzVyPUGuOlIyPTJizszN	MljBV2FPT0WU
BCPAP	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlu3TWM2OD1zLk[2OFU4KM7:TR?=	NXfOdY1sW0GQR1XS
22RV1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvpOJlKSzVyPUGuOlc5PDNizszN	MWfTRW5ITVJ?
T47D	NETtfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHmy[WlKSzVyPUGuOlgxPjFizszN	NH;OfIlUSU6JRWK=
MSTO-211H	NHPRXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTFwNkm2NFMh\|ryP	M1qzR3NCVkeHUh?=
DEL	NVrZe\|MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\YfpZ5UUN3ME2xMlcxOjd\|IN88US=>	MkX1V2FPT0WU
H4	MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvjTWM2OD1zLkezNlEzKM7:TR?=	MV7TRW5ITVJ?
CAL-51	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XzWGlEPTB;MT63OFg2PSEQvF2=	M4LzVnNCVkeHUh?=
ABC-1	M{Hxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Pl[WlEPTB;MT63PFU5OiEQvF2=	NFXwOYdUSU6JRWK=
MZ2-MEL	NULjdYxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfYUo5uUUN3ME2xMlc6PTR{IN88US=>	M4XOUnNCVkeHUh?=
YKG-1	NFLhWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwOEGwOlEh\|ryP	NH3PUVhUSU6JRWK=
KM12	M3PwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1i1TWlEPTB;MT64NVYxOiEQvF2=	MmftV2FPT0WU
L-363	M1LYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfvTWM2OD1zLki3OFEzKM7:TR?=	NIH6S4pUSU6JRWK=
KU812	M{jYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEX2[oVKSzVyPUGuPFkzQDJizszN	M2jLS3NCVkeHUh?=
LOXIMVI	M3vuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\zZ\|RpUUN3ME2xMlkyOjJ6IN88US=>	MmTWV2FPT0WU
G-401	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTFwOUK0Nlgh\|ryP	MlLhV2FPT0WU
SW780	NHrufoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmK4TWM2OD1zLkm2NlQ3KM7:TR?=	NHjScWpUSU6JRWK=
SW872	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\LclRyUUN3ME2xMlk5OzNizszN	MYPTRW5ITVJ?
NB7	NV\xZoV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7JXlY6UUN3ME2xMlk6OzJ\|IN88US=>	NFrxZoxUSU6JRWK=
T98G	NXf6PXR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJwMEC2OlYh\|ryP	NEjIeFFUSU6JRWK=
SW1710	NWe5UII4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTJwME[5OFUh\|ryP	NIXzZWhUSU6JRWK=
NCI-H1573	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHjTWM2OD1{LkC3Nlk5KM7:TR?=	NGWyNJhUSU6JRWK=
KE-37	NFv3[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHKbGZjUUN3ME2yMlA5QTVzIN88US=>	M3;LW3NCVkeHUh?=
786-0	MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y0dWlEPTB;Mj6xOVQ{QSEQvF2=	NH;GSGdUSU6JRWK=
SAS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILWVIJKSzVyPUKuNlA{PzRizszN	NYXudWtXW0GQR1XS
CAL-54	M2PWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moe4TWM2OD1{LkKwOFE{KM7:TR?=	MVXTRW5ITVJ?
SF268	NY\aS4VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\2OVBKSzVyPUKuNlMyOjJizszN	MnryV2FPT0WU
SW620	NV:yeIpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTJwMk[xOlkh\|ryP	M3e0RnNCVkeHUh?=
MN-60	M1TlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTJwM{GwOkDPxE1?	NYnwbmlXW0GQR1XS
EFO-27	NIXscoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTJwM{KwOVgh\|ryP	MlnIV2FPT0WU
NCI-H747	M1Xo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDHS29FUUN3ME2yMlMzOTl7IN88US=>	NEf6[YNUSU6JRWK=
HCC2218	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XTNmlEPTB;Mj6zOVM4PCEQvF2=	M2myS3NCVkeHUh?=
MIA-PaCa-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTMXmRKSzVyPUKuN\|Y1OzdizszN	NIHJSXRUSU6JRWK=
SJSA-1	NH3tS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjQ[HcxUUN3ME2yMlM4Pzl4IN88US=>	MWnTRW5ITVJ?
RKO	NWXRVmtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi1[5gxUUN3ME2yMlM5PDl4IN88US=>	M16wN3NCVkeHUh?=
NB6	M2nXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTJwNECzO\|Qh\|ryP	NIrmN49USU6JRWK=
ES4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEj1fXBKSzVyPUKuOFU1OjJizszN	NWDNfnl4W0GQR1XS
EGI-1	NVPkOZZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXFcXN3UUN3ME2yMlQ3QDh\|IN88US=>	NGToWXFUSU6JRWK=
CTV-1	NEXYdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TwUmlEPTB;Mj61Nlc4OyEQvF2=	NELBRWNUSU6JRWK=
NCI-H1355	NH3MRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELBfpBKSzVyPUKuOVU6PTFizszN	MWPTRW5ITVJ?
GT3TKB	NYr6NolPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkCxTWM2OD1{LkW5NVk6KM7:TR?=	NVfuO49RW0GQR1XS
SK-HEP-1	M1fPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXkTWM2OD1{LkW5NlY3KM7:TR?=	MWjTRW5ITVJ?
GAMG	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF6xSGJKSzVyPUKuOVk{QTRizszN	MlG4V2FPT0WU
SK-MES-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjrN3hKSzVyPUKuOlE5ODNizszN	M1HsWnNCVkeHUh?=
RO82-W-1	M4K1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\rTWM2OD1{Lk[yNFU4KM7:TR?=	NVnaeoZqW0GQR1XS
ECC10	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLnU4lGUUN3ME2yMlcxOjB4IN88US=>	MV7TRW5ITVJ?
MCF7	NEXiTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLWSYMzUUN3ME2yMlcyPDZ2IN88US=>	NUTMOlBCW0GQR1XS
D-283MED	M{H4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\I[GlvUUN3ME2yMlczPDNizszN	NFHmOIxUSU6JRWK=
RPMI-7951	NUDEN4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGX6NlhKSzVyPUKuO\|U3QTRizszN	NGTYZ4RUSU6JRWK=
Ramos-2G6-4C10	M3XXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJwN{ewPVkh\|ryP	NIDNbpNUSU6JRWK=
KGN	M1K0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTJwOEG4PFQh\|ryP	NVrISJFkW0GQR1XS
NUGC-3	NV6zVmNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HiTGlEPTB;Mj64NlUxPSEQvF2=	M{e0VXNCVkeHUh?=
NCI-H292	M2Xlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\YPGlEPTB;Mj64OVA2OyEQvF2=	NWnyWopWW0GQR1XS
Becker	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HIUWlEPTB;Mj65OVg{OiEQvF2=	MYfTRW5ITVJ?
NCI-H1299	NIS5bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTNwMEWyOlMh\|ryP	MXnTRW5ITVJ?
ETK-1	NGC1cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTNwMEW0N{DPxE1?	MWnTRW5ITVJ?
TK10	NHzwNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvhTZZPUUN3ME2zMlIxOTZ3IN88US=>	M1\yNHNCVkeHUh?=
VMRC-RCZ	Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;sTWM2OD1\|LkO2OFg5KM7:TR?=	MULTRW5ITVJ?
YH-13	NY[0dnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Pmd2lEPTB;Mz60OFA4QSEQvF2=	NVLkU3B3W0GQR1XS
DU-145	NHn0boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVu3NGljUUN3ME2zMlQ3OjZ7IN88US=>	NHfxc41USU6JRWK=
SW1088	MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XVOmlEPTB;Mz60O\|Q4KM7:TR?=	MXHTRW5ITVJ?
HOP-92	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnwU3NUUUN3ME2zMlUxOzR{IN88US=>	NFLmUWpUSU6JRWK=
KP-N-YS	M1vodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrYUplKSzVyPUOuOlIyOzlizszN	NHfBV4RUSU6JRWK=
NCI-H460	NH2xT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTNwNk[3N{DPxE1?	M1:4S3NCVkeHUh?=
U-2-OS	NY\k[2tnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vCXGlEPTB;Mz63NlU{PSEQvF2=	NFfIUnlUSU6JRWK=
A101D	NVfBVHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3UTWM2OD1\|Lke2PVM3KM7:TR?=	M4fu[nNCVkeHUh?=
MDA-MB-231	M33NSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTNwOEG5OVEh\|ryP	MV7TRW5ITVJ?
IST-MES1	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnOfYx1UUN3ME2zMlg{OiEQvF2=	NYfTcWhMW0GQR1XS
COR-L105	MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfHTWM2OD12LkCxPEDPxE1?	NFTGPXFUSU6JRWK=
NCI-H1437	NGfUVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoW1TWM2OD12LkCyN\|AzKM7:TR?=	NWPSTo5XW0GQR1XS
CAL-85-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYC4ZmM1UUN3ME20MlAzPDZzIN88US=>	NELxZZNUSU6JRWK=
MZ1-PC	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTRwMUi1OVYh\|ryP	M4XjWHNCVkeHUh?=
VM-CUB-1	NXvYWZh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHh[ppKSzVyPUSuN\|EzQDRizszN	NV7sNYhiW0GQR1XS
CHL-1	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TTc2lEPTB;ND6zNlE3QSEQvF2=	M1XiN3NCVkeHUh?=
MDA-MB-361	M{LDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIq2clFKSzVyPUSuN\|MyPTNizszN	M3\IbnNCVkeHUh?=
NCI-H661	NHixPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjaV4NCUUN3ME20MlUxODl{IN88US=>	M1PDdHNCVkeHUh?=
EW-11	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnmTWM2OD12LkWyNlMyKM7:TR?=	M3n6SXNCVkeHUh?=
BEN	NFXIfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonsTWM2OD12LkWyPFE2KM7:TR?=	NGDkeZRUSU6JRWK=
BFTC-909	M2e1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYe1R2p7UUN3ME20MlU3Ojd3IN88US=>	NFjlWpVUSU6JRWK=
NCI-H2087	M{TON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkKzTWM2OD12LkW4NVY1KM7:TR?=	MWfTRW5ITVJ?
RVH-421	M3zr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjrUnRKSzVyPUSuOlY3QSEQvF2=	M3X4TnNCVkeHUh?=
P30-OHK	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DCU2lEPTB;ND62PFAxQCEQvF2=	MkPMV2FPT0WU
NCI-H28	M1i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\vO2RKSzVyPUSuPFE3PjFizszN	MlLwV2FPT0WU
ES6	NYm0TmdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIr3Sm5KSzVyPUSuPFMxOTZizszN	Ml\kV2FPT0WU
769-P	NXzscHU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33ZemlEPTB;ND64OVkzPiEQvF2=	NVXpXGxWW0GQR1XS
OE33	NIrSXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGS2Z2pKSzVyPUSuPFgyPjFizszN	M4\KNXNCVkeHUh?=
SW982	NEj2dnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7rTWM2OD12Lkm1NFYyKM7:TR?=	M3;Wc3NCVkeHUh?=
A388	M{jyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;1TWM2OD13LkCyPVg{KM7:TR?=	M4TCe3NCVkeHUh?=
TI-73	NGTCW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzQ[nVKSzVyPUWuNFYyQTRizszN	NHLhN\|VUSU6JRWK=
HCT-116	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTkNVlHUUN3ME21MlA6QDh7IN88US=>	NX\zWWJEW0GQR1XS
HuP-T3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rIemlEPTB;NT6xPFcxQSEQvF2=	MWLTRW5ITVJ?
G-402	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\zTYRlUUN3ME21MlE6PDF4IN88US=>	M3;ZRXNCVkeHUh?=
NCI-H1792	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7tTWM2OD13LkK0OlIzKM7:TR?=	NID1ZXZUSU6JRWK=
NCI-H209	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXiwW4g6UUN3ME21MlI2QTR{IN88US=>	NXXiSlhFW0GQR1XS
NCI-H1650	M1fDO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXq1RWtvUUN3ME21MlMxPjN2IN88US=>	NYTYbYdVW0GQR1XS
LCLC-97TM1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTiOmdTUUN3ME21MlMyQDB6IN88US=>	MULTRW5ITVJ?
S-117	NFnmNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4GycWlEPTB;NT6zOlk4PiEQvF2=	NE\Nd49USU6JRWK=
GI-ME-N	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTVwM{m2PFEh\|ryP	NF;qVJNUSU6JRWK=
NCI-H2122	M2nzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NET3UI5KSzVyPUWuOFk{QTdizszN	M2P5O3NCVkeHUh?=
NCI-H1793	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17RTGlEPTB;NT62O\|U6OyEQvF2=	NIj3TopUSU6JRWK=
C2BBe1	M2X0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTVwN{CwPFgh\|ryP	M1XEOXNCVkeHUh?=
TE-12	M2[3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEezR5pKSzVyPUWuPFA2PTZizszN	NHmxOVFUSU6JRWK=
LCLC-103H	M2HHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nISWlEPTB;NT65NVch\|ryP	NFr6XG9USU6JRWK=
A673	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvifpBKSzVyPUWuPVE6OzJizszN	NEfnbolUSU6JRWK=
BB30-HNC	NWn4OmxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTVwOUizOkDPxE1?	MVPTRW5ITVJ?
SF295	NV7NeGJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDpTWM2OD14LkCwOFIzKM7:TR?=	MXLTRW5ITVJ?
KU-19-19	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vrcWlEPTB;Nj6wNVc{OSEQvF2=	MnvNV2FPT0WU
CFPAC-1	M3qwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPZTWM2OD14LkC0OFQ{KM7:TR?=	NIjyXZRUSU6JRWK=
LoVo	M37HV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnFe5RoUUN3ME22MlA2ODZ\|IN88US=>	MmTiV2FPT0WU
8505C	M1;5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTZwMEe1O\|Mh\|ryP	MWPTRW5ITVJ?
GMS-10	NUDY[5h7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnEc\|JiUUN3ME22MlE2ODB{IN88US=>	M17ZXHNCVkeHUh?=
Ca9-22	NX3WOnhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHqTWM2OD14LkG2O\|Eh\|ryP	MXHTRW5ITVJ?
DOK	NHm1eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILjfZlKSzVyPU[uNlIxPzJizszN	NVvafWluW0GQR1XS
FADU	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf1SGVKSzVyPU[uNlYxOzlizszN	NFHkbXhUSU6JRWK=
BxPC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\wOWlEPTB;Nj6yO\|MzKM7:TR?=	NVni[plFW0GQR1XS
CAL-33	NYnYWGpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz6b4tKSzVyPU[uNlkzODFizszN	MWPTRW5ITVJ?
SHP-77	NFr4OYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;0eFRtUUN3ME22MlMyPTF{IN88US=>	NXjxZmUzW0GQR1XS
LXF-289	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTZwM{O0OVUh\|ryP	M1n1b3NCVkeHUh?=
GB-1	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHSZVlKSzVyPU[uN\|gzKM7:TR?=	MVnTRW5ITVJ?
KS-1	MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTZwM{i0OFch\|ryP	NXLmeYY6W0GQR1XS
D-502MG	NXjpOJkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXkTWM2OD14LkSyN\|c3KM7:TR?=	MXXTRW5ITVJ?
LAN-6	NH7TU\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz5NpJKSzVyPU[uOVExOjNizszN	MWfTRW5ITVJ?
H-EMC-SS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIn4c3ZKSzVyPU[uOVYyPDdizszN	Moe4V2FPT0WU
LC-2-ad	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrHTWM2OD14Lk[wNFc3KM7:TR?=	NWjmT45VW0GQR1XS
NCI-H1693	NWq5[2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTZwNkKyNVUh\|ryP	MnntV2FPT0WU
SK-N-FI	NFTHUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2G5OWlEPTB;Nj63OVA1PCEQvF2=	NUj5cnVuW0GQR1XS
D-423MG	NEnteI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnhTWM2OD14Lke2NVE4KM7:TR?=	MXTTRW5ITVJ?
KNS-42	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDQdo5KSzVyPU[uO\|gyQTdizszN	NGH0bYxUSU6JRWK=
GCT	M2mzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLUTWM2OD14LkmzPEDPxE1?	NW\NWIlUW0GQR1XS
DSH1	Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTdwME[zN{DPxE1?	Mmr3V2FPT0WU
D-247MG	NFu3PZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHXTWM2OD15LkC3PFgyKM7:TR?=	M4r1V3NCVkeHUh?=
NCI-SNU-5	M3rMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXX2PG1yUUN3ME23MlE5OzdzIN88US=>	NGW4SHZUSU6JRWK=
TE-6	NHLGfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXSVox[UUN3ME23MlIxPjBzIN88US=>	MY\TRW5ITVJ?
NOMO-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkizTWM2OD15LkKyNVI4KM7:TR?=	M3z0U3NCVkeHUh?=
NB17	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHUTWM2OD15LkOwN\|A6KM7:TR?=	MnPFV2FPT0WU
EW-22	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTdwM{SzOFgh\|ryP	M2X3THNCVkeHUh?=
EW-13	NYDtSIlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTdwM{WxOlIh\|ryP	NYrXc3g3W0GQR1XS
DOHH-2	NGroNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrBSItnUUN3ME23MlQ1ODJizszN	M4PvdXNCVkeHUh?=
TGBC1TKB	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTZOnZWUUN3ME23MlQ6QDl7IN88US=>	MUnTRW5ITVJ?
GR-ST	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDjTWM2OD15LkWyOVk1KM7:TR?=	NV3XeWc5W0GQR1XS
KYSE-520	M1nYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLjNYhKSzVyPUeuOVU2OTVizszN	NF2xeIxUSU6JRWK=
CAPAN-1	M2i3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTdwNUm1NUDPxE1?	M1zpd3NCVkeHUh?=
HCE-4	NGX0eHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPQTWM2OD15Lk[yNlc6KM7:TR?=	NGPS[3NUSU6JRWK=
MLMA	M4P0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jC[mlEPTB;Nz62Nlk2PyEQvF2=	MXvTRW5ITVJ?
HT-144	M4LUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M374PGlEPTB;Nz62OVM3QCEQvF2=	NU\Jcmh6W0GQR1XS
KYSE-180	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fNUGlEPTB;Nz63NVE3QSEQvF2=	M2n6TnNCVkeHUh?=
TE-5	M3\aT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTdwOUW5O\|Eh\|ryP	MVvTRW5ITVJ?
IGROV-1	M3W3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;t[3BmUUN3ME23Mlk5PTVzIN88US=>	MlftV2FPT0WU
NCI-H1581	NH\pfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nSTmlEPTB;OD6wNVIh\|ryP	MkjGV2FPT0WU
SW1990	NFX1ZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRThwMES2OVkh\|ryP	MnHuV2FPT0WU
EFM-19	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\5TWM2OD16LkC4OVQ2KM7:TR?=	Mm\KV2FPT0WU
OGR-1	MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRThwNEOwNlMh\|ryP	Mln4V2FPT0WU
U-118-MG	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXST5VKSzVyPUiuOFM1PjNizszN	MXzTRW5ITVJ?
SK-OV-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRThwNE[3OlUh\|ryP	NGHlNVdUSU6JRWK=
KNS-62	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRThwNUG3OlEh\|ryP	NI\jc2RUSU6JRWK=
GOTO	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjUWo5KSzVyPUiuOVc3OzVizszN	M3\2c3NCVkeHUh?=
8305C	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfoVo9KSzVyPUiuO\|A1QDRizszN	MmrEV2FPT0WU
RPMI-2650	NVTvPG43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXz3flZwUUN3ME24MlcyQTV3IN88US=>	NIC0R5RUSU6JRWK=
NEC8	NGnmTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPxS4ZKSzVyPUiuO\|Q{ODdizszN	M4e3dHNCVkeHUh?=
KYSE-450	NIrkfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrxXm9lUUN3ME24Mlg3PTR6IN88US=>	NWLacoFyW0GQR1XS
RMG-I	M3SxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjCZnUzUUN3ME25MlE1ODV6IN88US=>	MnvSV2FPT0WU
CAKI-1	M4fjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHaTWM2OD17LkOxPVc6KM7:TR?=	M37ucHNCVkeHUh?=
KYSE-510	MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUToU4JqUUN3ME25MlM2Pzd6IN88US=>	NWjwTGp1W0GQR1XS
A4-Fuk	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;MNFlKSzVyPUmuN\|Y4ODFizszN	MojKV2FPT0WU
AN3-CA	Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PicmlEPTB;OT60OVQ1PCEQvF2=	MYfTRW5ITVJ?
SK-N-DZ	MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnOTWM2OD17LkeyPFQ6KM7:TR?=	NEHxepFUSU6JRWK=
HSC-2	NXLBUlM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHyXlJKSzVyPUmuO\|Y3OjlizszN	Mn7sV2FPT0WU
EW-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjjNYN5UUN3ME25Mlc6OzZ7IN88US=>	Mk\JV2FPT0WU
D-566MG	NHz6[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvzN4NKSzVyPUmuPFM3PjRizszN	MkT0V2FPT0WU
COLO-792	NX3WOIhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUSwclVRUUN3ME25Mlk5PzR4IN88US=>	NHvGTIRUSU6JRWK=
TE-10	M1TqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;5NWlEPTB;MUCuNFM6PiEQvF2=	M4PZ[HNCVkeHUh?=
NCI-H650	NYDQUW1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHj2b2pKSzVyPUGwMlQzQDZizszN	NVXPSnU3W0GQR1XS
U-266	M1my[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTFyLkS1OUDPxE1?	NFniPW5USU6JRWK=
Detroit562	NHrtUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPZTWM2OD1zMT6wOVE2KM7:TR?=	Mni5V2FPT0WU
NH-12	M1X0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWntXIJHUUN3ME2xNU4yPDR4IN88US=>	NUHabGh[W0GQR1XS
CO-314	NEPXfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLhTWM2OD1zMT6yPFQzKM7:TR?=	NXH5bGxOW0GQR1XS
IST-MEL1	M2DXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fONWlEPTB;MUGuOVMzOyEQvF2=	M3;RWHNCVkeHUh?=
KNS-81-FD	MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEO1dZpKSzVyPUGxMlU2OjdizszN	NFLvWJBUSU6JRWK=
SW1463	M17FOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjMTWM2OD1zMT61PVg6KM7:TR?=	M1PCO3NCVkeHUh?=
NCI-H23	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH[xNGZKSzVyPUGxMlY2PTJizszN	NV7jUHYxW0GQR1XS
SK-MEL-2	NXjPPGpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LQPGlEPTB;MUGuO\|E6PyEQvF2=	M1;GTHNCVkeHUh?=
NB13	M3jZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULjVZVbUUN3ME2xNk4yPDl3IN88US=>	MXPTRW5ITVJ?
Daoy	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTF{LkK4OVYh\|ryP	M3jTTnNCVkeHUh?=
NCI-H1623	NGLvRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYW3coM1UUN3ME2xNk4{QDBzIN88US=>	NG\DfpJUSU6JRWK=
NMC-G1	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVm3WVg3UUN3ME2xNk44OTdizszN	M37nSnNCVkeHUh?=
DK-MG	NI\JfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLHTY9uUUN3ME2xNk46PDh{IN88US=>	MWjTRW5ITVJ?
TCCSUP	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvFTWM2OD1zMz6xNlg1KM7:TR?=	MVHTRW5ITVJ?
SCC-15	M1nHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vXfmlEPTB;MUOuNlY2OSEQvF2=	MoDYV2FPT0WU
NOS-1	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojWTWM2OD1zMz6yPFk{KM7:TR?=	MU\TRW5ITVJ?
RH-1	M4XMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HMVWlEPTB;MUOuN\|A{PyEQvF2=	NXSwSo9iW0GQR1XS
SK-MEL-3	NUjVZ5N5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzoO4FKSzVyPUGzMlM4OjhizszN	MmLDV2FPT0WU
NB5	MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTF\|LkSwOlch\|ryP	NX7ufmY5W0GQR1XS
SNU-387	M1rhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTF\|LkWwO\|Ih\|ryP	NGPFeFhUSU6JRWK=
CAL-120	NWPS[JN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvUTWM2OD1zMz62O\|E5KM7:TR?=	NXnUbpRzW0GQR1XS
Mo-T	NVTRR4hvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1X4cGlEPTB;MUOuO\|A4KM7:TR?=	M3jn[3NCVkeHUh?=
LNCaP-Clone-FGC	NV3LPIw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTF\|Lke5PVIh\|ryP	Mnv5V2FPT0WU
CAN	M3jHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLUXXNMUUN3ME2xOE4xOjh6IN88US=>	NH\FNWpUSU6JRWK=
SK-MEL-30	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVztdZM2UUN3ME2xOE4xPjNizszN	MnuzV2FPT0WU
COLO-678	NXPpbYtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmWyTWM2OD1zND6wPFIzKM7:TR?=	M1fwfHNCVkeHUh?=
SCC-9	NH7qW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF2LkGwNlEh\|ryP	MWTTRW5ITVJ?
KINGS-1	M2LtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTTTWM2OD1zND6xOFAzKM7:TR?=	NX3nenduW0GQR1XS
SL-513	M1rIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkT0TWM2OD1zND6xPFch\|ryP	NVviV5ZFW0GQR1XS
HLE	NGfCPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2foSGlEPTB;MUSuN\|g2OiEQvF2=	NIPQS3VUSU6JRWK=
SW1573	NEjySZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorhTWM2OD1zND60OFM2KM7:TR?=	MVvTRW5ITVJ?
KYSE-140	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LiUmlEPTB;MUSuOlMzPyEQvF2=	NInnRWVUSU6JRWK=
SK-PN-DW	NX:z[m1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\3fWFKSzVyPUG0MlgxODFizszN	Mn3sV2FPT0WU
A253	M2PkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXuXJNbUUN3ME2xOU4xPjJ3IN88US=>	NWnw[oFEW0GQR1XS
CAL-12T	M1TNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LPPWlEPTB;MUWuOFY3OiEQvF2=	M1jJPXNCVkeHUh?=
COLO-679	NIL4SmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XM[mlEPTB;MUWuO\|Y5OyEQvF2=	MljGV2FPT0WU
UACC-257	MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHuxUVFKSzVyPUG2MlEzODFizszN	MmDwV2FPT0WU
U-87-MG	NFn0WGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjjcopKSzVyPUG2MlM2OjNizszN	NGjGNnlUSU6JRWK=
HCC1806	NVTOU\|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3X4PGlEPTB;MU[uO\|A4OSEQvF2=	MoPjV2FPT0WU
NCI-H2170	M2iyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfyTWM2OD1zNz6yOFQ5KM7:TR?=	MWnTRW5ITVJ?
AGS	NX;kTY9lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fBXmlEPTB;MUeuN\|gxQCEQvF2=	MVzTRW5ITVJ?
MEL-HO	NHjmbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjITWM2OD1zNz63OVA{KM7:TR?=	MlrRV2FPT0WU
SW48	NYjQdmFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDJWm9KSzVyPUG3Mlc4OTZizszN	NVz6Z5kyW0GQR1XS
HuP-T4	NVnxRWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF6LkCyNFYh\|ryP	NWXueIszW0GQR1XS
NCI-H720	NUnQenpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTmTWM2OD1zOD6xOFAzKM7:TR?=	M1PaWnNCVkeHUh?=
RCC10RGB	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mme3TWM2OD1zOD6xOlk4KM7:TR?=	MWnTRW5ITVJ?
HD-MY-Z	NH3XbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDWTWM2OD1zOD6yNlU1KM7:TR?=	MlTiV2FPT0WU
A427	NV7Md4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFewTItKSzVyPUG4MlUxQTRizszN	MmKxV2FPT0WU
HCC2998	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHy[WlKSzVyPUG4MlYxPTFizszN	MX7TRW5ITVJ?
EPLC-272H	M4Tqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXYTWM2OD1zOT6wOFM1KM7:TR?=	NGj1VmxUSU6JRWK=
C32	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvXWWFiUUN3ME2xPU4xPDVizszN	NVvBO\|h5W0GQR1XS
UMC-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTF7LkKxNlMh\|ryP	MoL5V2FPT0WU
CaR-1	M3TkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoP1TWM2OD1zOT62PFA1KM7:TR?=	NVzn[GNTW0GQR1XS
KYSE-410	M4rjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPpNmVKSzVyPUG5MlkyOzlizszN	MXLTRW5ITVJ?
HuCCT1	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTJyLk[yPVQh\|ryP	MX3TRW5ITVJ?
LB996-RCC	M3fnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJyLkexOlgh\|ryP	Mor6V2FPT0WU
KYSE-70	M4H5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWj0dW9WUUN3ME2yNE45ODV7IN88US=>	M4f6OHNCVkeHUh?=
CAL-72	NXTMbGM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJyLkmxOUDPxE1?	NGGxZ4hUSU6JRWK=
Capan-2	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7ROYV[UUN3ME2yNU4xPDF\|IN88US=>	M1LiWHNCVkeHUh?=
PANC-08-13	NWW3NZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJzLkK1NVUh\|ryP	MXPTRW5ITVJ?
SBC-1	NF63TW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmC4TWM2OD1{MT6zNFgyKM7:TR?=	MofnV2FPT0WU
MFM-223	M{X1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;mTWM2OD1{MT6zN\|QzKM7:TR?=	NVH0XGJKW0GQR1XS
BB49-HNC	NVf1eFNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjkXlNRUUN3ME2yNU42PzF4IN88US=>	M{ThPXNCVkeHUh?=
SH-4	M3q3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NECxOG5KSzVyPUKxMlY3OThizszN	MkG5V2FPT0WU
HuO9	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnwNHc6UUN3ME2yNU46QDJ3IN88US=>	MlLLV2FPT0WU
AM-38	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXOcGFKSzVyPUKyMlA1QDVizszN	M2LWdXNCVkeHUh?=
A431	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTJ\|LkKxNVkh\|ryP	M{Di[XNCVkeHUh?=
YAPC	NWHv[VZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7DTWM2OD1{Mz6yOlUyKM7:TR?=	NEj5W\|lUSU6JRWK=
LU-139	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7VTWM2OD1{Mz60PFA6KM7:TR?=	MoWyV2FPT0WU
HEC-1	NHf4[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHyTWM2OD1{Mz60PVM4KM7:TR?=	NIrHdGhUSU6JRWK=
SCC-25	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJ2LkOwNFYh\|ryP	NV\DZZlDW0GQR1XS
HT-29	NUiyV5lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknKTWM2OD1{ND6zPFI{KM7:TR?=	NEDDRVFUSU6JRWK=
PC-14	NXG3dW1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLCTWM2OD1{ND62OVcyKM7:TR?=	MVfTRW5ITVJ?
Calu-6	MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX2cGNKSzVyPUK1MlUxPzFizszN	NGDQdWRUSU6JRWK=
SJRH30	M17zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LRV2lEPTB;MkWuOlQ6PiEQvF2=	MVzTRW5ITVJ?
ChaGo-K-1	M2\XPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoC2TWM2OD1{Nj6xOlI6KM7:TR?=	MljRV2FPT0WU
IA-LM	M{XtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXaOW0xUUN3ME2yOk4{PjR3IN88US=>	MonPV2FPT0WU
GP5d	NEjLOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7leIxxUUN3ME2yOk41PDlzIN88US=>	MonUV2FPT0WU
NCI-H2291	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLZPVN6UUN3ME2yOk43PTRzIN88US=>	Moj1V2FPT0WU
BALL-1	NGL2OIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoW1TWM2OD1{Nj65N\|k4KM7:TR?=	MVTTRW5ITVJ?
HCC1954	M3P6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJ4Lkm4NFgh\|ryP	MVTTRW5ITVJ?
NCI-H2452	NFnTO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mof0TWM2OD1{Nz60NVY{KM7:TR?=	MlzCV2FPT0WU
LU-99A	MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjCbllKSzVyPUK3MlU2QDJizszN	NUPme2trW0GQR1XS
NTERA-S-cl-D1	MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHySItKSzVyPUK3MlczQTlizszN	NIfuNYNUSU6JRWK=
PANC-10-05	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHXTWM2OD1{Nz63O\|c2KM7:TR?=	MWTTRW5ITVJ?
NCI-H2405	M2\ZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3:wW2lEPTB;MkeuPVM5PyEQvF2=	MWnTRW5ITVJ?
MDA-MB-415	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHFTWM2OD1{OD60NVM4KM7:TR?=	NYXHVmJlW0GQR1XS
NCI-H2342	M4DOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fBW2lEPTB;MkiuOVI5OSEQvF2=	NGfW[pBUSU6JRWK=
TGBC24TKB	M{T2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoW4TWM2OD1{OD63NVE4KM7:TR?=	MXfTRW5ITVJ?
LU-134-A	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrwTWM2OD1{OD65NlYyKM7:TR?=	Mn7tV2FPT0WU
SCC-4	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{P2ZWlEPTB;M{GuNFQ6PCEQvF2=	MVPTRW5ITVJ?
Saos-2	NWn3bZhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYK3WIlFUUN3ME2zNU46OzB4IN88US=>	M{XoWnNCVkeHUh?=
RERF-LC-MS	NX;CO2tKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTRcnlyUUN3ME2zNk45OjNzIN88US=>	M2TiPXNCVkeHUh?=
M14	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zLO2lEPTB;M{KuPVc3PCEQvF2=	NHf0[5pUSU6JRWK=
HPAF-II	NIrjWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjvN\|BTUUN3ME2zN{42ODFzIN88US=>	MXnTRW5ITVJ?
NCI-H1755	Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLrTWM2OD1\|ND6zN\|A2KM7:TR?=	MVzTRW5ITVJ?
D-392MG	MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHW0VYtKSzVyPUO1Mlg3PzRizszN	MV;TRW5ITVJ?
A704	M3X4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\3bnR[UUN3ME2zOk4xPDJ5IN88US=>	MkGyV2FPT0WU
CP50-MEL-B	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTN4LkG5NVEh\|ryP	MlvSV2FPT0WU
EW-18	NYHHbmY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTN4LkS1NkDPxE1?	NWfHWGdlW0GQR1XS
WM-115	NXrGOmJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PETWlEPTB;M{[uPFA6QSEQvF2=	NUHHOFRKW0GQR1XS
LU-65	M2rOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rWcGlEPTB;M{euNVQyPyEQvF2=	MkjMV2FPT0WU
NCI-H1563	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLG[oRKSzVyPUO3MlI1QDRizszN	NYnocVNvW0GQR1XS
DBTRG-05MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPWeItKSzVyPUO4MlA3QTFizszN	NUHUOJllW0GQR1XS
NCI-H630	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfGRnVWUUN3ME2zPE41PzF2IN88US=>	NFXyWGRUSU6JRWK=
NCI-H1155	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPZTWM2OD1\|OT6yOFIh\|ryP	NYTsPFNDW0GQR1XS
OVACR-3	NYSxTWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPmXmpKSzVyPUO5MlkyQTVizszN	NYfJNGs2W0GQR1XS
OAW-42	NFXXcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2P3cWlEPTB;NECuOFI2QCEQvF2=	NUjSW294W0GQR1XS
JVM-2	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrpZWVKSzVyPUSxMlI1OTVizszN	NIjTTJJUSU6JRWK=
C3A	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTRzLkO0OFch\|ryP	M3jRN3NCVkeHUh?=
HT55	M2rH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHPOHh4UUN3ME20Nk4zQDRzIN88US=>	MWHTRW5ITVJ?
OVCAR-4	NYjEVoR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLvW3dYUUN3ME20Nk4zQTd2IN88US=>	NH;l[lVUSU6JRWK=
MEG-01	M4DDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3NTWM2OD12Mj60OlE3KM7:TR?=	M2HsTXNCVkeHUh?=
NCI-H82	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInPNoNKSzVyPUSzMlk5QTJizszN	MX7TRW5ITVJ?
JEG-3	NHvuOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjqcVdKSzVyPUS0Mlk1PyEQvF2=	MXHTRW5ITVJ?
BPH-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfyRYpKSzVyPUS2MlM6QThizszN	NEjnPVlUSU6JRWK=
MPP-89	NXvFe4FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjxeGxjUUN3ME20O{4zQDl6IN88US=>	M{jp[nNCVkeHUh?=
ALL-PO	M3f1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTITWM2OD12Nz60NVg5KM7:TR?=	Ml\wV2FPT0WU
HT	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTR5LkS5NkDPxE1?	MkPrV2FPT0WU
NCI-H2347	NYPXfZVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moe4TWM2OD12OD6wO\|E2KM7:TR?=	NU\NWo55W0GQR1XS
A2780	NEnFdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTR7LkSyNlgh\|ryP	MoXlV2FPT0WU
KARPAS-299	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTR7LkWxNVkh\|ryP	MmrsV2FPT0WU
NCI-H1651	NYfoU4Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\wWGlEPTB;NEmuPFgzOSEQvF2=	Ml;FV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	Cl.CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2N(C5CCCC5)C1=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04360941	Not yet recruiting	Drug: Palbociclib\|Drug: Avelumab	Triple Negative Breast Cancer\|Locally Advanced Breast Cancer\|Recurrent Breast Cancer\|Metastatic Breast Cancer\|ER+ Breast Cancer\|HER2-positive Breast Cancer	Royal Marsden NHS Foundation Trust\|Pfizer\|Breast Cancer Now	July 1 2020	Phase 1
NCT03870919	Suspended	Drug: Palbociclib\|Other: locoregional treatment	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	October 23 2019	Not Applicable
NCT03900884	Not yet recruiting	Drug: Venetoclax\|Drug: Palbociclib\|Drug: Letrozole	Breast Neoplasm Female	Peter MacCallum Cancer Centre Australia	September 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl